Granules India Receives 'Hold' Rating Upgrade

Granules India, a midcap pharmaceutical company, has recently received a 'Hold' rating from MarketsMOJO. This upgrade is based on the company's high management efficiency, with a ROCE of 18.15%, and its strong ability to service debt, with a low Debt to EBITDA ratio of 1.14 times. The company has also shown healthy long-term growth, with an annual operating profit growth rate of 30.27%. Technically, the stock is currently in a bullish range and has shown improvement since November 2023, generating a return of 15.07%. The MACD and KST technical factors are also bullish, indicating a positive trend for the stock. In terms of valuation, Granules India is currently trading at a discount compared to its average historical valuations, with an attractive ROCE of 15.1 and an Enterprise value to Capital Employed ratio of 2.6. However, the company has declared negative results for the last three consecutive quarters, with the lowest ROCE of 14.18% and the highest Debt-Equity ratio of 0.47 times. The interest for the quarter was also at its highest at Rs 25.96 crore. Despite these challenges, the company has a high institutional holding of 28.54%, indicating their confidence in the company's fundamentals. Their stake has also increased by 0.51% over the previous quarter, further highlighting their positive outlook for Granules India. Investors should keep a close eye on the company's performance in the upcoming quarters, but with its strong management efficiency and potential for long-term growth, Granules India remains a promising midcap player in the pharmaceutical industry.